Patent · US Active

Pyrido[2,3-B]pyrazin-8-substituted compounds and their use

US8912191B2 · kind B2 · utility

8Cited by
18References
20Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 24, 2013
Grant dateDec 16, 2014
Priority date
Expiry dateSep 24, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.